Latent Tuberculosis Infection (LTBI) Clinical Practice Guidelines (CDC, 2020)

National Tuberculosis Controllers Association (NTCA) and Centers for Disease Control and Prevention (CDC)

This is a quick summary of the guidelines without analysis or commentary. For more information, go directly to the guidelines by clicking the link in the reference.

March 02, 2020

The National Tuberculosis Controllers Association (NTCA) and Centers for Disease Control and Prevention (CDC) have issued updated treatment guidelines for latent tuberculosis infection (LTBI) among persons who live in the United States.[1]

The recommended 2020 LTBI treatment guidelines include three preferred rifamycin-based regimens and two alternative daily-isoniazid monotherapy regimens. These recommendations are intended for Mycobacterium tuberculosis infections with presumed susceptibility to isoniazid or rifampin. M tuberculosis strains that are resistant to both isoniazid and rifampin are exempt from these recommendations.

Generally, rifamycin-based treatment regimens administered in short courses are preferred over isoniazid monotherapy administered in longer courses for the treatment of LTBI.

Preferred Treatment Regimens for LTBI

The rifamycin-based preferred regimens for LTBI are as follows:

  • Once-weekly isoniazid plus rifapentine for 3 months (strongly recommended in adults and children >2 years, including those with HIV infection) OR

  • Daily rifampin for 4 months (strongly recommended in HIV-negative adults and children of all ages) OR

  • Daily isoniazid plus rifampin for 3 months (conditionally recommended in adults and children of all ages and in HIV-positive persons)

Prescribing providers or pharmacists should note that rifampin and rifapentine are not interchangeable, and care should be taken to administer the correct medication for the intended regimen.

Alternative Treatment Regimens for LTBI

The alternative treatment regimens are as follows:

  • Daily isoniazid for 6 months (strongly recommended in HIV-negative adults and children of all ages and conditionally in HIV-positive adults and children of all ages) OR

  • Daily isoniazid for 9 months (conditionally recommended in adults and children of all ages regardless of HIV infection status)

For more information, please go to Tuberculosis (TB).

For more Clinical Practice Guidelines, please go to Guidelines.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....